Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · June 11, 2023

Safety, Pharmacokinetics, and Pharmacodynamics of Orforglipron in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
Diabetes Obes Metab 2023 Jun 01;[EPub Ahead of Print], E Pratt, X Ma, R Liu, D Robins, T Coskun, KW Sloop, A Haupt, C Benson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading